BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/11/2020 2:04:35 PM | Browse: 122 | Download: 285
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Systematic Reviews |
Article Title |
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
|
Manuscript Source |
Invited Manuscript |
All Author List |
Takumi Onoyama, Yohei Takeda, Taro Yamashita, Wataru Hamamoto, Yuri Sakamoto, Hiroki Koda, Soichiro Kawata, Kazuya Matsumoto and Hajime Isomoto |
Funding Agency and Grant Number |
|
Corresponding Author |
Takumi Onoyama, MD, PhD, Doctor, Department of Multidisciplinary Internal Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Tottori prefecture, Japan. golf4to@yahoo.co.jp |
Key Words |
Nivolumab; Pembrolizumab; Avelumab; Durvalumab; Atezolizumab; Programmed cell death-1 inhibitor |
Core Tip |
This study systematically reviewed the literature on the programmed cell death-1 inhibitor-related sclerosing cholangitis. Biliary dilation without obstruction, diffuse hypertrophy of the extrahepatic biliary tract and/or multiple strictures of intrahepatic biliary tract, liver dysfunction with a notable increase in biliary tract enzymes relative to hepatic enzymes, normal level of the serum immunoglobulin G4, and a moderate to poor response to steroid therapy, and CD8+ T cell infiltration in the biliary tract were clinical and pathological features of programmed cell death-1 inhibitor-related sclerosing cholangitis. |
Citation |
Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 2020; 26(3): 353-365 |
|
Received |
|
2019-11-23 07:19 |
|
Peer-Review Started |
|
2019-11-23 07:19 |
|
To Make the First Decision |
|
|
|
Return for Revision |
|
2019-12-23 14:08 |
|
Revised |
|
2020-01-07 11:13 |
|
Second Decision |
|
2020-01-09 09:28 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-01-11 14:04 |
|
Articles in Press |
|
2020-01-11 14:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-01-13 14:02 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345